- Fraudulent Email Warning（27KB）
News Release
- March 25, 2026
- Announcement of Investment by Development Bank of Japan Inc. in a U.S. Subsidiary of NIPRO（324KB）
- March 24, 2026
- Notice Concerning Change in Depreciation Method（96KB）
- March 18, 2026
- Announcement of Spryte Medical, a US Affiliate of NIPRO, First Participants Enrolled in the “INSYTE” US Pivotal Trial evaluating the nOCT Imaging System during Brain Aneurysm Treatment（272KB）
IR News
- February 9, 2026
- Consolidated Financial Results for the Nine Months Ended December 31, 2025 [Japanese GAAP] / Notice Regarding Recording of Extraordinary Income (Gain on Step Acquisition) / IR Materials
- December 9, 2025
- The 73rd Interim Shareholders’ Newsletter
- November 21, 2025
- Toward NIPRO's Sustainable Growth
Our Business
Meeting the needs of front line medical treatment with unique products and technologies
To meet the needs of the front line of medical treatment, NIPRO creates unique products at its four research and development sites while leveraging the technologies cultivated in its various businesses.
Mission, Vision, Value
We will work as a truly global comprehensive medical manufacturer with a willingness to consider patient and user viewpoints.
